Alex Philippidis Senior News Editor Genetic Engineering & Biotechnology News
We’ve given last year’s Top 10 Pharma Firms list an update.
Last year, we gave you the top 10 pharma firms; this year, we turn the volume up to 15. Following is a list of 15 pharmaceutical companies, ranked by their market capitalization for the latest date that they furnished a figure for their numbers of outstanding shares and a year-ago figure for the same.
Pharmas, as with the biotechs listed in this space last week, benefited from the stock market surge that lifted share prices by mostly double-digit percentages over the past year. However, none of the 15 top pharma companies listed here had been able to double their market cap year-over-year; by contrast, five biotechs saw their market cap more than double over a 12-month period. Investors rewarded pharmas that performed well, though not as handsomely as biotechs that delivered.
Another factor in the lower market cap increases of pharmas compared with biotechs was the fact several of the companies were in the middle of restructuring efforts announced in earlier years, mostly related to loss of patent exclusivity on older blockbuster drugs. As reflected by GEN’s recent list of Top 15 Job-Cutting Companies of 2013 (So Far), pharmas carried out more job-cutting in the first half of 2013 compared with 2012.
The past year also saw some flux among the companies listed. Of this year’s top 15 (the 2012 GEN List of top pharmas included only 10 companies), two pharmas climbed up the list (Novartis and Sanofi); four slipped a notch or more (Roche, Merck & Co., GlaxoSmithKline, and AstraZeneca); three companies were ranked the same as last year; five were ranked for the first time (Bayer, Eli Lilly, Takeda, Astellas, and Daiichi Sankyo); and the remaining company (AbbVie) didn’t exist last year, rendering comparisons to 2012 moot.
#15. Daiichi Sankyo
2013 Market Cap: $12.876 billion (3/31: 704 million shares * price ¥1,815 on 3/29)1,2,3
2012 Market Cap: $10.701 billion (3/31: 704 million shares * price ¥1,508 on 3/30)1,2,3
% Change: 20.3%
Position on 2012 List: Not ranked
#14. Astellas
2013 Market Cap: $23.888 billion (3/31: 467.965 million shares * price ¥5,060 on 3/29)1,2,3
2012 Market Cap: $16.050 billion (3/31: 467.965 million shares * price ¥3,400 on 3/30)1,2,3
% Change: 48.8%
Position on 2012 List: Not ranked
#13. Takeda
2013 Market Cap: $40.056 billion (3/31: 789.666 million shares * price ¥5,030 on 3/29)1,2,3
2012 Market Cap: $29.027 billion (3/31: 789.666 million shares * price ¥3,645 on 3/30)1,2,3
% Change: 38.0%
Position on 2012 List: Not ranked
#12. AstraZeneca
2013 Market Cap: $62.475 billion (3/31: 1.250 billion shares * price $49.98 on 3/28)2
2012 Market Cap: $56.680 billion (3/31: 1.274 billion shares * price $44.49 on 3/30)2
% Change: 10.2%
Position on 2012 List: #10
#11. Eli Lilly
2013 Market Cap: $64.687 billion (4/20: 1,126,561,464 shares * price $57.42 on 4/19)4
2012 Market Cap: $46.312 billion (4/20: 1,160,415,307 shares * price $39.91)
% Change: 39.7%
Position on 2012 List: Not ranked
#10. AbbVie
2013 Market Cap: $64.584 billion (3/31: 1,583,729,114 shares * price $40.78 on 3/28)2
2012 Market Cap: N/A5
% Change: N/A5
Position on 2012 List: N/A5
#9. Bristol-Myers Squibb
2013 Market Cap: $67.657 billion (3/31: 1,642,551,939 shares * price $41.19 on 3/28)2
2012 Market Cap: $57.007 billion (3/31: 1,689,084,439 shares * price $33.75 on 3/30)2
% Change: 18.7%
Position on 2012 List: #9
#8. Bayer
2013 Market Cap: $87.527 billion (3/31: €66.545 billion)1,6
2012 Market Cap: $57.365 billion (3/31: €43.613 billion)1,6
% Change: 52.6%
Position on 2012 List: Not ranked
#7. GlaxoSmithKline
2013 Market Cap: $112.511 billion (3/31: 4.834 billion shares * 1,538.50p [£15.385] on 3/29)1,7,8
2012 Market Cap: $104.852 billion (3/31: 4.963 billion shares * 1,396.50p [£13.965] on 3/30)1,7,8
% Change: 7.3%
Position on 2012 List: #6
#6. Merck & Co.
2013 Market Cap: $141.922 billion (4/30: 3,019,611,844 shares * price $47.00)
2012 Market Cap: $118.710 billion (4/29: 3,086,584,896 shares * price $38.46 on 4/27)9
% Change: 19.6%
Position on 2012 List: #4
#5. Sanofi
2013 Market Cap: $148.381 billion (5/10: 1,324,058,064 shares * price €85.130)1,10
2012 Market Cap: $98.322 billion (5/10: 1,342,007,588 shares * price €55.660)1,10
% Change: 50.9%
Position on 2012 List: #8
#4. Roche
2013 Market Cap: $166.477 billion (1/1: CHF 156.582 billion)1,11
2012 Market Cap: $144.778 billion (1/1: CHF 136.102 billion)1,11
% Change: 15.0%
Position on 2012 List: #3
#3. Novartis
2013 Market Cap: $173.4 billion (6/30: 2,447,415,490 shares * price CHF 67.10)1,12
2012 Market Cap: $133.9 billion (6/30: 2,417,862,200 shares * price CHF 52.90)1,12
% Change: 29.5%
Position on 2012 List: #5
#2. Pfizer
2013 Market Cap: $203.717 billion (5/6: 7,093,223,330 shares * price $28.72)
2012 Market Cap: $168.109 million (5/7: 7,488,136,070 shares * price $22.45)
% Change: 21.2%
Position on 2012 List: #2
#1. Johnson & Johnson
2013 Market Cap: $248.393 billion (6/30: 2.8930 billion shares * price $85.86 on 6/28)13,14
2012 Market Cap: $189.046 billion (6/30: 2.7982 billion shares * price $67.56 on 6/29)13,14
% Change: 31.4%
Position on 2012 List: #1
Market cap is calculated by multiplying the number of outstanding shares by the share price. In some cases, companies furnished market cap figures directly, though usually rounded off. U.S. companies generally report their numbers of outstanding shares in their 10-Q quarterly or 10-K annual earnings filings with the Securities & Exchange Commission. Companies based outside the U.S. either disclose market cap directly, or their numbers of shares “in issue” or “in free issue” in half-year and full-year results disclosures. For all companies, closing share prices as of the dates of their outstanding-shares figures can be found through any of several free stock information websites. Figures of non-U.S. companies were converted to U.S. dollars from various currencies.
Notes:
1 Figures converted to U.S. dollars via www.xe.com on July 17, 2013.
2 Because March 31 was not a trading day in either 2013 or 2012, the closing price immediately preceding the date of share figure has been furnished.
3 Share figures furnished by the company to the nearest thousandth of a million.
4 Because April 20 was not a trading day in 2013, the closing price immediately preceding the date of share figure has been furnished.
5 AbbVie comprises the branded pharmaceutical operations spun out of Abbott Laboratories on January 2, 2013, so a comparison with 2012 is not available or N/A.
6 Company furnishes comparable market capitalization figures directly.
7 Share figures are weighted average number of shares for Q1 of 2013 and 2012, and were furnished by the company to the nearest thousandth of a billion.
8 Because March 31 was not a trading day in either 2013 or 2012, the closing price immediately preceding the date of share figure has been furnished.
9 Because April 29 was not a trading day in 2012, the closing price immediately preceding the date of share figure has been furnished.
10 Figures for numbers of shares disclosed by NYSE Euronext Paris exchange.
11 Company furnishes comparable market capitalization figures directly, but only to the nearest thousandth of a billion and only in its annual and half-year reports.
12 Company furnishes comparable market capitalization figures directly, but only to the nearest tenth of a billion.
13 Share figures are average number of shares outstanding (diluted) during Q2 2013 and 2012, and were furnished by the company in thousands of millions.
14 Because June 30 was not a trading day in either 2013 or 2012, the closing price immediately preceding the date of share figure has been furnished.
